A study looking at ADI PEG 20 to treat small cell lung cancer
Cancer type:
Status:
Phase:
This study looked at ADI PEG 20 for a type of lung cancer called small cell lung cancer (SCLC).
More about this trial


- how well ADI PEG 20 works for small cell lung cancer
- how safe it is
Summary of results
- 9 people who’d already had treatment for their SCLC that had worked
- 13 people who’d already had treatment for their SCLC that had not worked
- tiredness
- feeling sick
- drop in white blood cells
- loss of appetite
- soreness at the injection site
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Peter Szlosarek
Supported by
Barts Health NHS Trust
Ludwig Institute for Cancer Research
Polaris Pharmaceuticals Inc
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040